...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 15 Months

9 months exactly today since last webcast and 15 months exactly today since first dosing of the single agent ZEN-3694 trial.

Share
New Message
Please login to post a reply